


CASSINI

Trial description: High-risk ambulatory patients with cancer were randomized to rivaroxaban 10 mg daily (n = 420) vs. placebo (n = 421) for up to 180 days.



RESULTS

- Primary outcome: Proximal deep-vein thrombosis (DVT) in a lower limb, pulmonary embolism, symptomatic DVT in an upper limb or distal DVT in a lower limb, or death from venous thromboembolism at 180 days: 6.0% of rivaroxaban vs. 8.8% of placebo group (p = 0.10)

CONCLUSIONS

- Among high-risk patients with cancer, rivaroxaban was not superior to placebo at preventing venous thromboembolic events

Khorana AA, et al. N Engl J Med 2019;380:720-8



AMERICAN
COLLEGE of
CARDIOLOGY